Technology
Health
Biotechnology

Neurocrine

$78.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.04 (-1.30%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Neurocrine and other stocks, options, ETFs, and crypto commission-free!

About

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. Read More The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Employees
585
Headquarters
San Diego, California
Founded
1992
Market Cap
7.28B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
889.48K
High Today
$79.12
Low Today
$77.42
Open Price
$78.99
Volume
208.37K
52 Week High
$126.98
52 Week Low
$64.72

Collections

Technology
Health
Biotechnology
Pharmaceutical
US
North America

News

Seeking AlphaMay 21

AbbVie launches higher dose Orilissa

AbbVie (NYSE:ABBV) and licensor Neurocrine Biosciences (NASDAQ:NBIX) announce the commercial availability of the 200 mg twice-daily regimen (for up to six months) of ORILISSA (elagolix) for the treatment of moderate to severe pain associated with endometriosis.

537
PR NewswireMay 7

Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019

SAN DIEGO, May 7, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 14, 2019, in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of th...

89
Associated PressMay 7

Peloton Therapeutics Appoints Timothy P. Coughlin and Thilo Schroeder, Ph.D. to its Board of Directors

DALLAS--(BUSINESS WIRE)--May 7, 2019--Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced that Timothy P. Coughlin, former Chief Financial Officer of Neurocrine Biosciences, Inc., and Thilo Schroeder, Ph.D., Partner at Nextech Invest, Ltd. and former Peloton Board Observer, have been appointed to its Board of Directors. Steve Winick, J.D., Managing Director of Topspin Partners, who has been a direct...

23

Earnings

-$1.12
-$0.57
-$0.03
$0.52
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 30, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.